PortView
Direxion mRNA (MSGR) ETF Holdings & Analysis
ETFOther
What MSGR does
Under typical circumstances, this fund dedicates a minimum of 80% of its holdings to the securities that make up its benchmark index, or to other investments possessing comparable financial traits. The underlying index focuses on companies at the forefront of innovation and practical application of messenger RNA (mRNA) technology. These businesses are publicly traded on exchanges in the United States, Canada, and across Europe. It is important to note that this fund operates as a non-diversified investment.
Fund profile
Top holdings
| Holding | Weight | |
|---|---|---|
| Vertex Pharmaceuticals | 8.09% | |
| BeiGene Ltd | 7.51% | |
| Arcturus Therapeutics Holdings Inc | 7.45% | |
| SCLX | 6.82% | |
| Alnylam Pharmaceuticals Inc | 6.45% | |
| PTC THERAPEUTICS INC USD 0.001 | 6.31% | |
| BIONTECH SE | 5.76% | |
| Moderna Inc | 5.60% | |
| SAREPTA THERAPEUTICS INC | 5.30% | |
| Maravai LifeSciences Holdings Inc | 4.93% |
Geographic allocation
| United States | 89.32% |
| Germany | 9.15% |
| Netherlands | 1.54% |
PortView Portfolio Insights
PortView analyzes how MSGR fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze MSGR in PortView →Related securities
Related stocks
Frequently asked questions
- What does MSGR track?
- MSGR is the Direxion mRNA ETF, a Other ETF.
- What is the expense ratio of MSGR?
- Expense ratio data for MSGR is shown on the page when available from our data provider.
- What are the largest holdings in MSGR?
- Top holdings include VRTX, BGNE, ARCT, SCLX, ALNY.
- How can PortView analyze MSGR overlap with other ETFs?
- PortView computes the holdings overlap between MSGR and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.